FACEPHI BIOMETRIA SA (ALPHI.PA) Fundamental Analysis & Valuation

EPA:ALPHI • ES0105029005

Current stock price

2.29 EUR
-0.01 (-0.43%)
Last:

This ALPHI.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALPHI.PA Profitability Analysis

1.1 Basic Checks

  • ALPHI had negative earnings in the past year.
  • In the past year ALPHI had a positive cash flow from operations.
  • In the past 5 years ALPHI reported 4 times negative net income.
  • In multiple years ALPHI reported negative operating cash flow during the last 5 years.
ALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

  • With a Return On Assets value of -19.65%, ALPHI is not doing good in the industry: 83.64% of the companies in the same industry are doing better.
  • ALPHI has a Return On Equity of -46.24%. This is amonst the worse of the industry: ALPHI underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -19.65%
ROE -46.24%
ROIC N/A
ROA(3y)-7.9%
ROA(5y)-7.67%
ROE(3y)-20.34%
ROE(5y)-18.76%
ROIC(3y)N/A
ROIC(5y)N/A
ALPHI.PA Yearly ROA, ROE, ROICALPHI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • ALPHI has a Gross Margin of 53.83%. This is in the lower half of the industry: ALPHI underperforms 64.55% of its industry peers.
  • In the last couple of years the Gross Margin of ALPHI has declined.
  • ALPHI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.32%
GM growth 5Y-11.24%
ALPHI.PA Yearly Profit, Operating, Gross MarginsALPHI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ALPHI.PA Health Analysis

2.1 Basic Checks

  • ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ALPHI has more shares outstanding
  • The number of shares outstanding for ALPHI has been increased compared to 5 years ago.
  • The debt/assets ratio for ALPHI has been reduced compared to a year ago.
ALPHI.PA Yearly Shares OutstandingALPHI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALPHI.PA Yearly Total Debt VS Total AssetsALPHI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of 1.27, we must say that ALPHI is in the distress zone and has some risk of bankruptcy.
  • ALPHI has a Altman-Z score of 1.27. This is in the lower half of the industry: ALPHI underperforms 65.45% of its industry peers.
  • The Debt to FCF ratio of ALPHI is 5.75, which is a neutral value as it means it would take ALPHI, 5.75 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 5.75, ALPHI is in line with its industry, outperforming 49.09% of the companies in the same industry.
  • A Debt/Equity ratio of 0.04 indicates that ALPHI is not too dependend on debt financing.
  • ALPHI has a better Debt to Equity ratio (0.04) than 80.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 5.75
Altman-Z 1.27
ROIC/WACCN/A
WACC9.11%
ALPHI.PA Yearly LT Debt VS Equity VS FCFALPHI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 1.00 indicates that ALPHI should not have too much problems paying its short term obligations.
  • The Current ratio of ALPHI (1.00) is worse than 71.82% of its industry peers.
  • A Quick Ratio of 1.00 indicates that ALPHI may have some problems paying its short term obligations.
  • The Quick ratio of ALPHI (1.00) is worse than 71.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 1
ALPHI.PA Yearly Current Assets VS Current LiabilitesALPHI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ALPHI.PA Growth Analysis

3.1 Past

  • The earnings per share for ALPHI have decreased strongly by -11.54% in the last year.
  • The Revenue has grown by 11.11% in the past year. This is quite good.
  • The Revenue has been growing by 28.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-11.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)11.11%
Revenue growth 3Y30.13%
Revenue growth 5Y28.76%
Sales Q2Q%8.33%

3.2 Future

  • Based on estimates for the next years, ALPHI will show a very strong growth in Earnings Per Share. The EPS will grow by 29.14% on average per year.
  • Based on estimates for the next years, ALPHI will show a quite strong growth in Revenue. The Revenue will grow by 19.34% on average per year.
EPS Next Y94%
EPS Next 2Y46.63%
EPS Next 3Y36.8%
EPS Next 5Y29.14%
Revenue Next Year25.74%
Revenue Next 2Y24.47%
Revenue Next 3Y21.66%
Revenue Next 5Y19.34%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALPHI.PA Yearly Revenue VS EstimatesALPHI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
ALPHI.PA Yearly EPS VS EstimatesALPHI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2

More info and screens

Find the best growth stocksShow best growing peers

3

4. ALPHI.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 44.90, ALPHI can be considered very expensive at the moment.
  • ALPHI's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 23.68. ALPHI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 44.9
ALPHI.PA Price Earnings VS Forward Price EarningsALPHI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALPHI is valued a bit more expensive than the industry average as 64.55% of the companies are valued more cheaply.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as ALPHI.
Industry RankSector Rank
P/FCF 37.36
EV/EBITDA 43.28
ALPHI.PA Per share dataALPHI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ALPHI's earnings are expected to grow with 36.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.63%
EPS Next 3Y36.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALPHI.PA Dividend Analysis

5.1 Amount

  • No dividends for ALPHI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALPHI.PA Fundamentals: All Metrics, Ratios and Statistics

FACEPHI BIOMETRIA SA

EPA:ALPHI (4/9/2026, 7:00:00 PM)

2.29

-0.01 (-0.43%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)10-20
Earnings (Next)04-27
Inst Owners30.01%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap59.04M
Revenue(TTM)30.00M
Net Income(TTM)-7.86M
Analysts82.5
Price Target3.4 (48.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-250.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.9
P/S 1.97
P/FCF 37.36
P/OCF 7.7
P/B 3.47
P/tB 11.81
EV/EBITDA 43.28
EPS(TTM)-0.29
EYN/A
EPS(NY)0.05
Fwd EY2.23%
FCF(TTM)0.06
FCFY2.68%
OCF(TTM)0.3
OCFY12.99%
SpS1.16
BVpS0.66
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.65%
ROE -46.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.83%
FCFM 5.27%
ROA(3y)-7.9%
ROA(5y)-7.67%
ROE(3y)-20.34%
ROE(5y)-18.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.32%
GM growth 5Y-11.24%
F-Score5
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 5.75
Debt/EBITDA 0.48
Cap/Depr 101.67%
Cap/Sales 20.3%
Interest Coverage N/A
Cash Conversion 485.44%
Profit Quality N/A
Current Ratio 1
Quick Ratio 1
Altman-Z 1.27
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)134.94%
Cap/Depr(5y)175.33%
Cap/Sales(3y)22.27%
Cap/Sales(5y)23.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y94%
EPS Next 2Y46.63%
EPS Next 3Y36.8%
EPS Next 5Y29.14%
Revenue 1Y (TTM)11.11%
Revenue growth 3Y30.13%
Revenue growth 5Y28.76%
Sales Q2Q%8.33%
Revenue Next Year25.74%
Revenue Next 2Y24.47%
Revenue Next 3Y21.66%
Revenue Next 5Y19.34%
EBIT growth 1Y37.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year199.27%
EBIT Next 3Y61.98%
EBIT Next 5Y44.47%
FCF growth 1Y110.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y164.15%
OCF growth 3YN/A
OCF growth 5YN/A

FACEPHI BIOMETRIA SA / ALPHI.PA Fundamental Analysis FAQ

What is the fundamental rating for ALPHI stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALPHI.PA.


Can you provide the valuation status for FACEPHI BIOMETRIA SA?

ChartMill assigns a valuation rating of 3 / 10 to FACEPHI BIOMETRIA SA (ALPHI.PA). This can be considered as Overvalued.


How profitable is FACEPHI BIOMETRIA SA (ALPHI.PA) stock?

FACEPHI BIOMETRIA SA (ALPHI.PA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ALPHI stock?

The Earnings per Share (EPS) of FACEPHI BIOMETRIA SA (ALPHI.PA) is expected to grow by 94% in the next year.


Can you provide the dividend sustainability for ALPHI stock?

The dividend rating of FACEPHI BIOMETRIA SA (ALPHI.PA) is 0 / 10 and the dividend payout ratio is 0%.